Overview
- Becton Dickinson reported adjusted earnings of $3.96 per share for the quarter, topping the $3.92 consensus.
- Fiscal 2026 adjusted EPS is guided to $14.75–$15.05, implying high single-digit operational growth with company outlook calling for low single-digit revenue growth.
- First-quarter revenue is projected to decline in the low single digits, with EPS of $2.75–$2.85 reflecting an estimated five-point tax headwind versus last year.
- The company expects its Biosciences & Diagnostic Solutions combination with Waters to close around the end of Q1 2026, generating a $4 billion cash distribution with at least half earmarked for share repurchases and the rest for debt reduction.
- BD raised its quarterly dividend 1% to $1.05 per share and noted strength in vascular access, infusion systems, oncology devices, and surgery, with China policies expected to trim about 100 basis points from revenue growth.